Article
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2011
Wu Jenn-Yu, Yu Chong-Jen, Chang Yeun-Chung, Yang Chih-Hsin, Shih Jin-Yuan, Yang Pan-Chyr
Abstract excerpt
PURPOSE: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R, deletions in exon 19, T790M, and insertions in exon 20, in non-small cell lung cancer (NSCLC) are well known. The clinical significance of other uncommon EGFR mutations, such as their association with the effe...
Topics
- Adult
- Aged
- Aged, 80 and over
- Amino Acid Substitution
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male
- Middle Aged